|drug2695||Pulmonary and Motor Rehabilitation Wiki||1.00|
|drug3383||The standard therapy Wiki||1.00|
|D055370||Lung Injury NIH||0.18|
|D016638||Critical Illness NIH||0.13|
|D014777||Virus Diseases NIH||0.10|
There is one clinical trial.
Clinical Role of Testosterone and Dihydrotestosterone and which of them should be inhibited in COVID-19 patients - A double-edged sword? COVID-19 attacks and affects Males significantly more than females , . Males with COVID-19 are reported to die at twice the rate of females when they come infected with the virus . The upregulation of TMPRSS2 by androgens could explain the increased susceptibility to COVID-19 in men.Contrary to expected, as a study demonstrated that The expression level of TMPRSS2 increased 6-fold in androgen stimulated LNCaP cells, relative to androgen-deprived cells. But, surprisingly, low levels of testosterone led to the over expression and upregulation of ACE2 and TMPRSS2 receptors, facilitating SARS-CoV-1 entry into the alveolar cells, and deregulating a lung-protective pathway .According to literature Dihydrotestosterone is many times more potent than testosterone, and many of the effects that testosterone has in the body only happen after it is converted to dihydrotestosterone . Therefore, we hypothesis that testosterone has better effect than dihydrotestosterone in case of COVID-19, because a study found that DHT significantly induced the expression of TMPRSS2 . And at the same time , decreased testosterone levels in critically diseased males harmfully affect pulmonary endothelial cell functioning, impair the ability to clear the virus , promote systemic . Obesity among males, promote defective immune response, , and also generates more pro-inflammatory cytokines important in cell signaling, emanating in increased, severe disease, worst outcome and vulnerability. Insufficient serum testosterone level is a poor prognostic indicator for patients infected with COVID-19 by downregulation pulmonary protective pathways , . On the contrary, high testosterone levels can lead to complication of thrombosis which is also one of the serious manifestations in COVID-19 patients. Thereby we hypothesize that decreased testosterone levels in men have a direct relation with the severity of infection and a worse outcome in COVID-19. In this case we should found an appropriate treatment that induces testosterone level to introduce its protective effect and up regulate pulmonary protective pathways and at the same time protect against thrombosis and works to reduce the impact of dihydrotestosterone on lung cells preventing up regulation of TMPRSS2, Her we shed new light on the appropriate treatment can overcome the challenges that face testosterone therapy in the era of COVID-19 After searching MEDLINE , PubMed, , Google Scholar, preprints and Controlled Trials until September , 2020 we found that the appropriate treatment in this case is aerosolized 13 cis retinoic acid in combination with testosterone therapy, as more than one study found that 13 cis retinoic acid reversibly and potentially inhibit the effect of dihydrotestosterone on different targeted cells. In addition its impact on thrombin.
Description: Proportion of lung injury score decreased or increased after treatmentMeasure: lung injury score Time: at 7and 14 days
Description: lymphocyte countsMeasure: Absolute lymphocyte counts Time: at 7and 14 days
Description: Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferonMeasure: Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon Time: at 7and 14 days
Description: Serum level of COVID19 RNAMeasure: Serum level of COVID19 RNA Time: at 7and 14 days
Description: Angiotensin 1-7 (Ang 1-7) changes over timeMeasure: Angiotensin 1-7 (Ang 1-7) changes over time Time: at 7and 14 days
Description: Angiotensin 1-5 (Ang 1-5) changes over timeMeasure: Angiotensin 1-5 (Ang 1-5) changes over time Time: at 7and 14 days
Description: Renin changes over timeMeasure: Renin changes over time Time: at 7and 14 days
Description: Aldosterone changes over timeMeasure: Aldosterone changes over time Time: at day 7 and 14
Description: Angiotensin-converting enzyme (ACE) changes over timeMeasure: Angiotensin-converting enzyme (ACE) changes over time Time: at day 7 and 14
Description: Frequency of adverse events and severe adverse eventsMeasure: Frequency of adverse events and severe adverse events Time: at day 7 and 14
Description: Transe membrane protease ,serine II (TMPRSS2) changes over timeMeasure: Transe membrane protease ,serine II (TMPRSS2) changes over time Time: day 7 and 14
Description: Testosterone levels changes over timeMeasure: Testosterone levels changes over time Time: day 7 and 14
Description: Dihydrotestosterone(DHT) levels changes over timeMeasure: Dihydrotestosterone(DHT) levels changes over time Time: day 7 and 14
Description: Cholesterol levels changes over timeMeasure: Cholesterol levels changes over time Time: day 7 and 14
Description: Thrombin time (TT)Measure: Thrombin time (TT) Time: day 7 and 14
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports